



# REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

---

- **Description** p.1
- **Abstracting and Indexing** p.1
- **Editorial Board** p.1
- **Guide for Authors** p.4



ISSN: 1507-1367

### DESCRIPTION

---

*Reports of Practical Oncology and Radiotherapy* is an interdisciplinary bimonthly journal, publishing original contributions in clinical oncology and radiotherapy, as well as in radiotherapy physics, techniques and radiotherapy equipment.

*Reports of Practical Oncology and Radiotherapy* is a journal of the Polish Society of Radiation Oncology, the Czech Society of Radiation Oncology, the Hungarian Society for Radiation Oncology, the Slovenian Society for Radiotherapy and Oncology, the Polish Study Group of Head and Neck Cancer, the Guild of Bulgarian Radiotherapists and the Greater Poland Cancer Centre, affiliated with the Spanish Society of Radiotherapy and Oncology, the Portuguese Society of Radiotherapy–Oncology, the Romanian Society of Radiotherapy and Medical Oncology, the Latin American Association for Radiation Oncology and the Grupo Oncológico Catalan Occitano.

Wersja pierwotną czasopisma jest wersja internetowa.

### ABSTRACTING AND INDEXING

---

Index Copernicus  
Elsevier BIOBASE/Current Awareness in Biological Sciences  
EMBASE/Excerpta Medica  
Scopus

### EDITORIAL BOARD

---

#### **Editor-in-Chief**

**Julian Malicki**, The Greater Poland Cancer Centre, Poznań, Poland

#### **Co-Editors**

##### **Clinical**

**Albert Biete**, Universitat de Barcelona (Hospital Clínic), Dept. of Radiation and Oncology, Barcelona, Spain

**Tatiana Hadjieva**, University Hospital St. Sofia, Dept. of Radiotherapy, Sofia, Bulgaria

**Jirí Petera**, Medical Faculty Hospital, Hradec Králové New, Czech Republic

**Adela Poitevin**, Médica Sur, Dept. of radiation and oncology, Tlalpan, Mexico

**Primož Strojjan**, Institute of Oncology Ljubljana, Dept. of Teleradiotherapy, Ljubljana, Slovenia

## **Biology**

**Boguslaw Maciejewski**, Maria Sklodowska-Curie Memorial Institute, Ctr. of Oncology, Gliwice, Poland

## **Brachytherapy**

**Ovidiu Florin Coza**, Institute of Oncology in Cluj-Napoca, Dept. of Oncologic Radiotherapy, Cluj-Napoca, Romania

**Maria De Lurdes Trigo**, Instituto Português de Oncologia de Francisco Gentil, Lisboa, Portugal

**Ferran Guedeà**, L'Hospitalet de Llobregat, Dept. of Radiation Oncology, Barcelona, Spain

**Csaba Polgar**, National Institute of Oncology, Dept. of Radiotherapy, Budapest, Hungary

## **Physics**

**Julian Malicki**, The Greater Poland Cancer Centre, Poznań, Poland

## **Surgical Oncology**

**Wojciech Gokusinski**, The Greater Poland Cancer Centre, Dept. of Surgical Oncology, Poznań, Poland

## **Editorial Office**

### **Medical Consultant**

**Piotr Martenka**, The Greater Poland Cancer Centre, Dept. of Surgical Oncology, Poznań, Poland

**Piotr Milecki**, The Greater Poland Cancer Centre, Dept. of Radiation Oncology & Radiotherapy, Poznan, Poland

### **Statistical Editor**

**Michał Michalak**

### **Administrative Assistant**

**Sylwia Ciesińska**, The Greater Poland Cancer Centre, Dept. of Radiation Oncology & Radiotherapy, Poznan, Poland

### **Language Editor**

**Bradley Londres**, Catalan Institute of Oncology, Hospital Duran i Reynals, Barcelona, Spain

## **Editorial Board**

**Dimos Baltas**, Sana Klinikum Offenbach, Dept. of Medical Physics & Engineering, Offenbach, Germany

**Harry Bartelink**, The Netherlands Cancer Institute, Dept. of Radiotherapy, Amsterdam, Netherlands

**Ruud Brakenhoff**, Vrije Universiteit Medisch Centrum (VUMC), Dept. of Otolaryngology/Head&Neck Surgery, Amsterdam, Netherlands

**Antoni Castel**, USP Instituto Universitario Dexeus, Barcelon, Spain

**Laura Cerezo Padellano**, Hospital Universitario La Princesa, Dept. of Medicine, Madrid, Spain

**Jean Chavaudra**, Institut Gustave-Roussy in Villejuif, Villejuif Cedex, France

**Joanna.E Cygler**, Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada

**Maria De Lurdes Trigo**, Instituto Português Oncologia Porto FG, EPE, Serviço de Braquiterapia, Porto, Portugal

**Andreas Dietz**, Universität Leipzig, Dept. of Ear, Nose and Throat Medicine/Plastic Surgery, Leipzig, Germany

**Maria Do Carmo Lopes**, Instituto Português de Oncologia de Francisco Gentil, Dept. of Oncology, Lisboa, Portugal

**Peter Dunscombe**, University of Calgary, Alberta, Canada

**David Feltl**, University Hospital Ostrava, Ostrava, Czech Republic

**Jacek Fijuth**, Uniwersytet Medyczny w Łodzi, Dept. of Radiation Therapy and Oncology, Lodz, Poland

**János Fodor**, National Institute of Oncology, Dept. of Radiotherapy, Budapest, Hungary

### **Roumen Gabrovski**

**Anna Gasińska**, Cancer Center and Institute of Oncology, Dept. of Radiation Biology, Kraków, Poland

**Bogdan Gliński**, The Cancer Center and Institute of Oncology, Dept. of Radiation Oncology, Kraków, Poland

**Alfonso Gomez-Iturriaga**, Cruces University Hospital, Bizkaia, Department of Radiation Oncology, Bizkaia, Spain

**Reidar Grenmar**, Turku University Hospital, Dept. of Otorhinolaryngology-Head and Neck Surgery, Turku, Finland

**Ákos Gulybán**, European Organisation for Research and Treatment of Cancer (EORTC), Dept. of Oncotherapy, Brussels, Belgium

**Asuncion Hervas**, Hospital Ramón y Cajal, Oncología Radioterápica, Madrid, Spain

**Jacek Jassem**, Uniwersyteckie Centrum Kliniczne, Dept. of radiation and oncology, Gdańsk, Poland

**Barbara Jereczek-Fossa**, Istituto Europeo di Oncologia (IEO), Dept. of Radiation and oncology, Milano, Italy

**Gabriel Kacso**, Prof. Dr. Ion Chiricută Oncological Institute, Dept. of Oncology and Radiotherapy, Cluj-Napoca, Romania

**Joanna Kaźmierska**, The Greater Poland Cancer Centre, Dept. of Radiation Oncology & Radiotherapy, Poznan, Poland

**György Kovács**, Universität zu Lübeck, Lübeck, Germany

**Marco Krengli**, Azienda Ospedaliero Universitaria, Novara, Italy

**Sunil Krishnan**, The University of Texas MD Anderson Cancer Center, Dept. of Radiation Oncology, Houston, Texas, USA

**Jiri Kubes**, Proton Therapy Center, Prague, Prague, Czech Republic

**Pedro C. Lara**, Hospital Universitario de Gran Canaria, Dept. of Radiation Oncology, Las Palmas de Gran Canaria, Spain

**C René Leemans**, Vrije Universiteit Medisch Centrum (VUMC), Dept. of ENT- Head and Neck Surgery, Amsterdam, Netherlands

**Jan Willem Leer**, Radboudumc, Dept. of Radiation Oncology, Nijmegen, Netherlands

**Hotimir Lešnicar**, Institute of Oncology Ljubljana, Dept. of Oncology and Radiotherapy, Ljubljana, Slovenia

**Carla Lopes De Castro**, Instituto Português de Oncologia de Francisco Gentil, Dept. of Oncology, Lisboa, Portugal

**Miquel Macia**, Institut Català d' Oncologia, IDIBELL, CIBERESP

**Andrzej Mackiewicz**, The Greater Poland Cancer Centre, Dept. of Cancer Immunology, Poznan, Poland

**Tibor Major**, National Institute of Oncology, Dept. of Radiotherapy, Budapest, Hungary

**Ginette Marinello**, Hôpital Henri Mondor, Créteil, France

**Lena Marinova**, Oncology Hospital, Dept. of Radiotherapy, Sofia, Bulgaria

**Janina Markowska**, Poznan University of Medical Sciences, Dept. of Oncology, Poznań, Poland

**Andrzej Marszałek**, Poznan University of Medical Sciences, Dept. of Tumor Pathology, Poznań, Poland

**Michał Michalak**

**Piotr Milecki**, The Greater Poland Cancer Centre, Poznan, Poland

**Luis Angel Montero**, Hospital Universitario Ramón y Cajal, Dept. of Radiation Oncology, Madrid, Spain

**Paweł Murawa**, The Greater Poland Cancer Centre, Dept. of Surgical Oncology, Poznań, Poland

**Viorica Magdalena Nagy**, Iuliu Hațieganu University of Medicine and Pharmacy, Dept. of Radiation Oncology, Cluj-Napoca, Romania

**Jan Olofsson**, Haukeland University Hospital, Dept. of Otolaryngology, Bergen, Norway

**Veselina Parvanova**

**Luis A. Perez Romasanta**, Hospital Clínico Universitario de Salamanca, Dept. of Medical Oncology, Salamanca, Spain

**Primož Peterli**, Institute of Oncology Ljubljana, Dept. of Medical Physics, Ljubljana, Slovenia

**Ervin B Podgorsak**, Montreal General Hospital, Dept. of Radiation Oncology, Montreal, Quebec, Canada

**Maria Esmeralda Poli**, Hospital de Santa Maria, Lisboa, Portugal

**Philip Poortmans**, Radboudumc, Dept. of Radiation Oncology, HB Nijmegen, Netherlands

**Richard Pötter**, Allgemeines Krankenhaus Wien (AKH), Dept. of Radiotherapy, Wien, Austria

**Vincenzo Ravo**, National cancer institute pascale foundation, Dept. of Oncology, Napoli, Italy

**Andrzej Roszak**, The Greater Poland Cancer Centre, Poznan, Poland

**Angeles Roviro**, Universitat de Barcelona (Hospital Clínic), Dept. of Radiation and Oncology, Barcelona, Spain

**Maria del Carmen Rubio Rodriguez**, Hospital Universitario Sancharro, Madrid, Spain

**Francisco Sanchez-Doblado**, Universidad de Sevilla, Fac. de Medicina, Sevilla, Spain

**Beata Sas-Korczyńska**, Cancer Center and Institute of Oncology, Dept. of tumor Biology, Kraków, Poland

**Pierre Scalliet**, University Hospital St Luc, Dept. of Radiation Oncology, Brussels, Belgium

**Jan Skolyszewski**

**Krzysztof Skłodowski**, Cancer Center and Institute of Oncology, Dept. of Radiation Oncology, Gliwice, Poland

**Vratislav Strnad**, Universitätsklinikum Erlangen, Dept. of Radiation Oncology, Erlangen, Germany

**Rafał Tarnawski**, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Dept. of Radiotherapy, Gliwice, Poland

**Vaneja Velenik**, Institute of Oncology Ljubljana, Dept. of Radiotherapy, Ljubljana, Slovenia

**Jacek Wachowiak**, University of Medical Sciences, Dept. of Pediatric Hematology, Oncology and Transplantation, Poznan, Poland

**Michał Waligórski**, Cancer Center and Institute of Oncology, Dept. of medical physics, Kraków, Poland

**Rodney Withers**, UCLA School of Medicine, Dept. of Radiation Oncology, Los Angeles, California, USA

**Matjaz Zwitter**, Institute of Oncology Ljubljana, Dept. of Oncology, Ljubljana, Slovenia

**Maja Čemažar**, Univerza na Primorskem, Dept. of Health Sciences, Isola, Slovenia

**Pavel Šlampa**, Masaryk Memorial Cancer Center, Dept. of Radiation Oncology, Brno, Czech Republic

## GUIDE FOR AUTHORS

---

### INTRODUCTION

#### *Criteria for manuscripts*

The Editorial Board of *Reports of Practical Oncology and Radiotherapy* takes under consideration for publication original articles with the understanding that neither the manuscript nor any part of its essential substance, tables or figures have been published previously in print form or electronically and are not under consideration by any other publication or electronic medium. This restriction does not apply to abstracts or press reports published in connection with scientific meetings. Copies of any closely related manuscripts should be submitted to the Editor along with the manuscript that is to be considered by *RPOR*.

*RPOR* discourages the submission of more than one article dealing with related aspects of the same study.

Each submission packet should include the statement signed by the first author that the work has not been published previously or submitted elsewhere for review and a copyright transfer.

#### *Categories of articles*

Accepted papers are published in the following journal sections: original papers (not more than 10 pages) review articles (not more than 8 pages) preliminary communications for rapid communication of preliminary data (not more than 4 pages) technical notes (not more than 2 pages) letters to the Editor for comments on recent articles (not more than 1 page) case reports (not more than 8 pages)

### BEFORE YOU BEGIN

#### *Ethics in publishing*

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

#### *Human and animal rights*

If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans <http://www.wma.net/en/30publications/10policies/b3/index.html>; EU Directive 2010/63/EU for animal experiments [http://ec.europa.eu/environment/chemicals/lab\\_animals/legislation\\_en.htm](http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm); Uniform Requirements for manuscripts submitted to Biomedical journals <http://www.icmje.org>. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

#### *Conflict of interest*

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also <http://www.elsevier.com/conflictsofinterest>. Further information and an example of a Conflict of Interest form can be found at: [http://help.elsevier.com/app/answers/detail/a\\_id/286/p/7923](http://help.elsevier.com/app/answers/detail/a_id/286/p/7923).

#### *Submission declaration and verification*

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <http://www.elsevier.com/editors/plagdetect>.

#### *Contributors*

Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.

### **Changes to authorship**

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

*Before the accepted manuscript is published in an online issue:* Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

*After the accepted manuscript is published in an online issue:* Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

### **Clinical trial results**

In line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.

### **Reporting clinical trials**

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram can be found on <http://www.consort-statement.org>.

### **Registration of clinical trials**

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors (ICMJE, <http://www.icmje.org>) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright see <http://www.elsevier.com/copyright>). Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>.

### **Retained author rights**

As an author you (or your employer or institution) retain certain rights; for details you are referred to: <http://www.elsevier.com/authorsrights>.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### **Funding body agreements and policies**

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

### **Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

### **Informed consent and patient details**

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the *Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals*, <http://www.elsevier.com/patient-consent-policy>. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

#### *Submit your article*

Please submit your article via <http://ees.elsevier.com/rpor>.

### **Review process**

Manuscripts are evaluated on the basis that they present new insights to the investigated topic, are likely to contribute to a research progress or change in clinical practice or in thinking about a disease. It is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled. Received manuscripts are first examined by the *RPOR* editors. Manuscripts with insufficient priority for publication are rejected promptly. Incomplete packages or manuscripts not prepared in the advised style will be sent back to authors without scientific review. The authors are notified with the reference number upon manuscript registration at the Editorial Office. The registered manuscripts are sent to independent experts for scientific evaluation. We encourage authors to suggest the names of possible reviewers, but we reserve the right of final selection. The evaluation process usually takes 1-3 weeks. Submitted papers are accepted for publication after a positive opinion of the independent reviewers.

### **Permissions**

Materials taken from other sources must be accompanied by a written statement from both author and publisher giving permission to *RPOR* for reproduction. Obtain permission in writing from at least one author of papers still in press, unpublished data, and personal communications.



## **Disclaimer**

Every effort is made by the Editor-in-Chief and the Editorial Board of *RPOR* to see that no inaccurate or misleading data, opinion or statement appear in the *Reports of Practical Oncology and Radiotherapy*. However, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor, sponsor or advertiser concerned. Accordingly, the Editor-in-Chief and the Editorial Board accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. Every effort is made to ensure that drug doses and other quantities are presented accurately. Nevertheless, readers are advised that methods and techniques involving drug usage and other treatments described in *RPOR*, should only be followed in conjunction with the drug or treatment manufacturer's own published literature in the readers own country.

## **PREPARATION**

### **Double-blind review**

This journal uses double-blind review, which means that both the reviewer and author name(s) are not allowed to be revealed to one another for a manuscript under review. The identities of the authors are concealed from the reviewers, and vice versa. For more information please refer to <http://www.elsevier.com/reviewers/peer-review>. To facilitate this, please include the following separately:

*Title page (with author details)*: This should include the title, authors' names and affiliations, and a complete address for the corresponding author including telephone and e-mail address.

*Blinded manuscript (no author details)*: The main body of the paper (including the references, figures, tables and any Acknowledgements) should not include any identifying information, such as the authors' names or affiliations.

### **Use of word processing software**

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

### **Article structure**

#### *Subdivision - unnumbered sections*

Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

#### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

#### *Material and methods*

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

#### *Results*

Results should be clear and concise.

#### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

## Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

## Appendices

All files named appendix or marked as such will **NOT** be published in the journal as they are treated as additional materials and will be available **only in the online version** of the article.

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

## Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**

- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

## Acknowledgements

Collate acknowledgements in a separate section and include it on the title page only. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

## Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Abstract should be included in the Blinded Manuscript. Abstracts for **Original Articles** should be structured, not exceed 250 words and should consist of five paragraphs labeled: Aim, Background, Materials and Methods, Results, Conclusion. Each section should begin on a new line and briefly describe, respectively, the purpose of the study, how the investigation was performed, the most important results and the principal conclusion that authors draw from the results.

## Keywords

Immediately after the abstract, provide a maximum of 5 keywords avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

## Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

## Math formulae

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).



## Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

## Artwork

### *Electronic artwork*

#### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the printed version.
- Submit each illustration as a separate file.

A detailed guide on electronic artwork is available on our website:

<http://www.elsevier.com/artworkinstructions>

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### *Formats*

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

#### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

#### *Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. Please indicate your preference for color: in print or on the Web only. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>.

#### *Figure captions*

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

## Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

## References

### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

### *Reference management software*

This journal has standard templates available in key reference management packages EndNote (<http://www.endnote.com/support/enstyles.asp>) and Reference Manager (<http://refman.com/support/rmstyles.asp>). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

Other software that can be used for reference management: RefWorks (<http://www.refworks.com>), BibTeX (<http://www.bibtex.org>), ProCite (<http://www.procite.com>).

### *Reference style*

*Text:* Indicate references by superscript numbers in the text. The actual authors can be referred to, but the reference number(s) must always be given.

*List:* Number the references in the list in the order in which they appear in the text.

### *Examples:*

Reference to a journal publication:

1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. *J Sci Commun* 2010;**163**:51–9.

Reference to a book:

2. Strunk Jr W, White EB. *The elements of style*. 4th ed. New York: Longman; 2000.

Reference to a chapter in an edited book:

3. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. *Introduction to the electronic age*, New York: E-Publishing Inc; 2009, p. 281–304.

Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (*J Am Med Assoc* 1997;**277**:927–34) (see also [http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html)).

### *Journal abbreviations source*

Journal names should be abbreviated according to the List of Title Word Abbreviations: <http://www.issn.org/services/online-services/access-to-the-ltwa/>.

### **Video data**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at

<http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### **Supplementary data**

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

### **Submission checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Phone numbers

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
  - References are in the correct format for this journal
  - All references mentioned in the Reference list are cited in the text, and vice versa
  - Permission has been obtained for use of copyrighted material from other sources (including the Web)
- For any further information please visit our customer support site at <http://support.elsevier.com>.

## **AFTER ACCEPTANCE**

### **Use of the Digital Object Identifier**

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

<http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

## **Offprints**

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on [ScienceDirect](#). This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (<http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (<http://webshop.elsevier.com/myarticleservices/booklets>).

## **AUTHOR INQUIRIES**

You can track your submitted article at [http://help.elsevier.com/app/answers/detail/a\\_id/89/p/8045/](http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/). You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.

© Copyright 2014 Elsevier | <http://www.elsevier.com>